In pulmonary arterial hypertension (PAH), antiapoptotic, proliferative, and inflammatory diatheses converge to create an obstructive vasculopathy. A selective down-regulation of the Kv channel Kv1.5 has been described in human and animal PAH. The resultant increase in intracellular free Ca 2؉ ([Ca 2؉ ]i) and K ؉ ([K ؉ ]i) concentrations explains the pulmonary artery smooth muscle cell (PASMC) contraction, proliferation and resistance to apoptosis. The recently described PASMC hyperpolarized mitochondria and increased bcl-2 levels also contribute to apoptosis resistance in PAH. The cause of the Kv1.5, mitochondrial, and inflammatory abnormalities remains unknown. We hypothesized that these abnormalities can be explained in part by an activation of NFAT (nuclear factor of activated T cells), a Ca 2؉ / calcineurin-sensitive transcription factor. We studied PASMC and lungs from six patients with and four without PAH and blood from 23 PAH patients and 10 healthy volunteers. 
T
he remodeled pulmonary arteries (PA) in pulmonary arterial hypertension (PAH) are characterized by vasoconstriction, suppressed apoptosis, and increased proliferation within the vascular wall (1) . Endothelial dysfunction, an early abnormality in PAH, leads to an increase in vasoconstrictors (like endothelin) over vasodilators (like prostacyclin) (2) . Correction of these abnormalities by blockade of the endothelin axis or enhancement of the prostacyclin axis is the basis of the current treatment for PAH; however the morbidity and mortality remains high (3) . More effective therapies for PAH will have to directly and selectively target the mechanisms leading to the proproliferative and antiapoptotic environment in the vascular wall; the recently described abnormalities in the PA smooth muscle cell (PASMC) K ϩ channels and mitochondria are such mechanisms (2, (4) (5) (6) (7) .
A selective down-regulation of PASMC Kv channels, like Kv1.5, has been described both in human (7) and animal models of PAH (6, (8) (9) (10) . This causes depolarization, opening of the voltage-gated Ca 2ϩ channels, and increase in intracellular free Ca 2ϩ concentration ([Ca 2ϩ ] i ). The increased [Ca 2ϩ ] i can explain both the vasoconstriction and the PASMC proliferation (11) . Kv1.5 channel downregulation also causes an increase in intracellular K ϩ concentration ([K ϩ ] i ) (inhibiting the efflux of K ϩ down its concentration gradient), which results in caspase inhibition. In several cell types, ranging from neurons, cancer cells, and PASMC, increased [K ϩ ] i directly inhibits caspases and apoptosis (12) (13) (14) . The mechanism for the down-regulation of Kv1.5 channel expression in PAH remains unknown.
In human and animal PAH, there appears to be a mitochondrial remodeling, as suggested by hyperpolarized PASMC mitochondria, compared with normal PASMC (4, 5) . The increased mitochondrial membrane potential (⌬⌿m) might be a marker of apoptosis resistance, because apoptosis is typically initiated by decrease in ⌬⌿m and efflux of proapoptotic mediators. Most carcinomas have increased ⌬⌿m (15, 16) . ⌬⌿m is regulated by metabolic or molecular mechanisms. Members of the bcl-2 family can directly control ⌬⌿m and apoptosis by interacting with the mitochondrial voltage-dependent anion channel or forming channels in mitochondrial membranes. The antiapoptotic bcl-2 prevents the decrease in ⌬⌿m induced by proapoptotic stimuli by enhancing H ϩ efflux from the mitochondria (17) and is up-regulated in human PAH (18) .
These PAH abnormalities (down-regulated Kv channels, upregulated bcl-2, hyperpolarized mitochondria) at first appear unrelated. However, there is evidence that they might be related. For example, bcl-2 inhibits Kv channels, whereas the proapoptotic cytochrome c activates Kv channels in PASMC (14) . In addition, dichloroacetate, an inhibitor of the mitochondrial enzyme pyruvate dehydrogenase kinase, reverses the mitochondrial hyperpolarization in both PAH (6) and cancer (12) and inhibits vascular remodeling and cancer growth; remarkably, in both conditions, it also reverses the down-regulation of Kv1.5, suggesting the presence of a mitochondria-Kv channel axis. We hypothesized that the Kv channel and mitochondria abnormalities might be ''choreographed'' by a ''master regulator,'' such as a transcription factor (19) .
Recent observations alerted us to the possibility that the nuclear factor of activated T cells (NFAT) might be involved in PAH. First, NFAT activation causes myocardial down-regulation of Kv1.5 (20) . Second, endothelin [which is up-regulated in PAH (2)] activates NFAT, which in turn increases bcl-2 expression, contributing to the prosurvival and antiapoptotic effects of endothelin in the heart (21) . Third, NFAT regulates the transcription of several metabolic and mitocondrial genes [like adenylosuccinate synthetase 1 (22) , heart fatty acid binding protein, pyruvate decarboxylase, cytochrome c oxidase, and succinate dehydrogenase (23) ]. In NFAT knockout models, embryonic lethality follows myocardial mitochondrial dysfunction due to suppressed respiration and oxidative capacity (23) , all of which are reversed by myocardial NFAT overexpression (23) .
NFAT, originally described in T cells, is a master activator of T cells, increasing the transcription of multiple inflammatory mediators and activating T and B cells (24) . Increased [Ca 2ϩ ] i activates calcineurin, which dephosphorylates cytoplasmic NFAT, allowing its entry to the nucleus, where it forms complexes with other transcription factors (like GATA or AP1) and regulates gene transcription (24) . The role of NFAT is now recognized in many cellular functions, beyond inflammation (19, 24, 25) . Inflammation also plays an understudied role in PAH; increased inflammatory mediators have been reported in serum and within the remodeled PA of PAH patients and a clinical association exists between PAH and autoimmune diseases like scleroderma (26) (27) (28) . We hypothesized that the ionic, mitochondrial, and inflammatory remodeling in PAH have a common denominator, i.e., a ''generalized'' activation of NFAT. This ''unifying'' hypothesis for the pathogenesis of PAH also suggests that NFAT inhibition might be therapeutically beneficial.
Results
NFATc2 Activation in Human PAH, But Not Normal PAs, in Vivo. We studied 11 human lungs, 6 with PAH, 4 normals (transplant donors), and 1 with thromboembolic disease [supporting information (SI) Table 1 ]. In normal and secondary pulmonary hypertension small PAs, there was low expression of NFATc2, which was almost always cytoplasmic, i.e., inactive (Fig. 1 ). In the same small PAs, there was strong expression of Kv1.5. In contrast, in all PAH PAs, there was up-regulation of NFATc2, which was translocated to the nucleus (i.e., activated) in most cells within the PA wall. In these remodeled PAs, there was a significant down-regulation of Kv1.5. Staining with only secondary antibodies revealed no signal, supporting the antibody specificity (SI Fig. 7A ). To study whether NFAT activation is sustained in vitro and whether NFAT dynamically regulates Kv channel expression, mitochondrial function, and apoptosis, we used human cultured normal and PAH PASMC.
NFATc2 Activation in iPAH PASMC. Compared with normal, idiopathic PAH (iPAH) PASMC have less total and 4-aminopyridinesensitive K ϩ current density (i.e., Kv) and depolarized membrane potential (Em) (Fig. 2A) ( Fig. 2B ), activated NFATc2 ( Fig. 2C) , and decreased Kv1.5 expression (Fig. 2D ). Whereas Ͼ60% of iPAH PASMC show NFATc2 activation ( Fig. 2C ), only Ϸ20% are positive for activated NFATc3 (SI Fig. 7B ). NFATc4 is present in several iPAH PASMC, but is activated in Ͻ5% of cells (SI Fig. 7B ). None of the NFAT isoforms are significantly present or active in normal PASMC. Thus, NFATc2 is the predominant NFAT isoform in iPAH PASMC.
We then used a direct and specific inhibitor of NFAT [i.e., VIVIT (29) ] and an indirect inhibitor [i.e., cyclosporine A (CSA)] to dynamically study NFAT activation and its downstream effects. We used a commercially available form of VIVIT with enhanced cell permeability due to the addition of an 11-arginine repeat. To address potential nonspecific effects of this small peptide, we also studied a nonactive cell-permeable small peptide with a similar structure (high arginine and lysine content) used to facilitate the cellular entry of viruses or drugs [i.e., antennapedia (30) ]. Both VIVIT (but not antennapedia) and CSA-treated iPAH PASMC have cytoplasmic and not nuclear NFATc2, increased outward K ϩ current (and decreased [K ϩ ]); increased Em, and decreased [Ca 2ϩ ] i ( Fig. 2) , with values essentially restored to those of normal PASMC. Most of the VIVIT-induced current is 4-AP sensitive, in keeping with Kv1.5 up-regulation ( Fig. 2 A and D) . Both VIVIT and CSA-treated PASMCs are also smaller, as shown by the decreased capacitance, an electrophysiological surrogate for cell size (Fig.  2 A) . This is likely due to both efflux of K ϩ and net osmotic loss and it is compatible with early apoptosis, which is associated with cell shrinkage (14) .
We have shown that PAH PASMC have hyperpolarized mitochondria compared with healthy PASMC and hypothesized that this is a marker of apoptosis resistance (4-6). Both VIVIT and CSA (but not antennapedia) depolarized PASMC mitochondria, essentially normalizing ⌬⌿m (Fig. 3A) . The mitochondrial depolarization led to efflux of the proapoptotic cytochrome c (Fig. 3B) and induction of iPAH PASMC apoptosis (Fig. 3C) . The induction of apoptosis, and not necrosis, was shown because the treated PASMC were annexin-positive but propidium iodide-negative. Both CSA and VIVIT (but not antennapedia) increased the percentage of TUNEL-positive cells and decreased PASMC proliferation (percentage of proliferating cell nuclear antigen-positive cells). This decrease in proliferation is related to the Ca 2ϩ -lowering effects of VIVIT and CSA, which is in turn related to their ability to reverse the Kv channel down-regulation.
iPAH PASMC have increased expression of the antiapoptotic bcl-2 compared with normal PASMC, and this is reversed by VIVIT (Fig. 3D) . Moreover, VIVIT results in displacement of bcl-2 from the mitochondria; although in PAH PASMC bcl-2 colocalizes with the mitochondrial marker mitotracker, in VIVIT-treated cells this colocalization is lost (Fig. 3D) . To further study the dynamic nature of the effects of NFAT, we studied normal PASMC exposed to chronic hypoxia, which causes a phenotype similar to iPAH, characterized by down-regulation of Kv channels, increased [Ca 2ϩ ] i , and proliferation and hyperpolarization of mitochondria (4, 9, 31). 9A ). The hypoxiainduced increase in PASMC ⌬⌿m (4, 5) was reversed by VIVIT (SI Fig. 8D ). The VIVIT-induced mitochondrial depolarization led to apoptosis, shown by efflux of cytochrome c (SI Fig. 9B ), increase in %TUNEL-positive cells (SI Figs. 8D and 9C) , activation of caspase 9 (SI Fig. 9C ), and staining for annexin (SI Fig. 10A ). VIVIT also decreased proliferation (decreased BrdU uptake and proliferating cell nuclear antigen expression) (SI Figs. 8D and 10B ).
NFATc2 and Inflammation in PAH.
Because products of activated immune cells, like interleukins, are increased in PAH patients, we determined whether activated NFAT (in addition to the lungs) can also be detected in the circulating cells. We studied two groups, in addition to control normal volunteers: a group of scleroderma-PAH (scl-PAH) patients, which, along with iPAH, belongs to the ''PAH superfamily'' (3) (SI Table 1 ). scl-PAH is characterized by a strong inflammatory component and worse prognosis than iPAH (3). We also studied a group with severe secondary pulmonary hypertension (thromboembolic disease, pulmonary fibrosis) to exclude the possibility that NFAT activation in circulating cells might be caused by the stress of cells passing through the remodeled PAs. CD3-positive T lymphocytes were found in the resistance PAs from all PAH patients but not in normal controls (Fig. 4A and SI Table  2 ). The majority of CD3-positive cells also showed NFATc2 activation.
We then studied white blood cells from the buffy coat of fresh blood. In 9 of 11 iPAH patients and in all scl-PAH, there was evidence of nuclear NFATc2. In contrast, in healthy volunteers (who did not have any evidence of cardiovascular, systemic disease, active or recent inflammation, or infection), cells had either no detectable or inactive (cytoplasmic) NFATc2 (Fig. 4B ). PAH patients also had higher levels of NFATc2 mRNA (qRT-PCR in buffy coat samples), compared with normal volunteers or secondary pulmonary hypertension. Although 2 of 11 iPAH patients had NFATc2 levels that overlapped those in normal or secondary pulmonary hypertension subjects, every scl-PAH patient had much higher levels of NFATc2 in circulating white cells (Fig. 4B) .
NFAT Inhibition Reverses Established Rat PAH. The reversal of iPAH phenotype in isolated human PASMC suggested that CSA might reverse PAH in vivo. After 2 weeks of oral CSA therapy (1 mg/kg, similar to the dose used clinically) in rats with established PAH [3 weeks post injection of monocrotaline (4-6)], total pulmonary vascular resistance and mean PA pressure were decreased and cardiac output increased (Fig. 5A) . CSA therapy decreased right ventricular hypertrophy (Fig. 5A ) and medial hypertrophy of smallmedium PAs (Ϸ100-400 m) (Fig. 5B) . CSA up-regulated PA Kv1.5 in vivo, shown by immunohistochemistry and immunoblots in isolated PAs (Fig. 5B ). In the same PAs, net NFATc2 expression was decreased and expressed NFAT was inactive (not in nucleus). PAs from CSA-treated rats had increased levels of activated caspase-9 and decreased ratio of bcl-2/bax, indicative of enhanced mitochondria-dependent apoptosis (Fig. 5B ).
Discussion
We show that NFAT is activated in human and animal PAH and that this activation explains several molecular hallmarks of this mysterious disease. NFAT activation contributes significantly to Kv1.5 down-regulation, bcl-2 up-regulation, and mitochondrial hyperpolarization, all of which contribute to a resistance to apoptosis within the PA wall. We provide evidence of a generalized activation of NFAT in circulating cells that could contribute to the inflammatory component of vascular remodeling and form the basis of ''biomarker'' discovery strategies. We demonstrate that NFAT inhibition is therapeutically beneficial in an accepted experimental model of PAH. Recently, there is interest in developing specific NFAT inhibitors, such as the VIVIT peptide we used, which does not inhibit calcineurin activity nonspecifically, but blocks the docking of calcineurin on NFAT itself (29) Table 2 ). However, ther was no correlation between NFATc2 levels and pulmonary vascular resistance in these cohorts. * , P Ͻ 0.05 vs. healthy controls. cardiac hypertrophy and failure (32) . Such ''transcriptional factor''-targeted therapies may bypass the nonspecific effects of other clinically used NFAT inhibitors like CSA and FK506 and therefore avoid many of their toxicities (32) . Although the clinical use of peptides is challenging, limited by antigenicity, proteolysis, or selective tissue delivery, our work suggests that novel NFATinhibiting strategies should be considered in human PAH. An advantage of treating PAH with NFAT inhibitors is that they might not only reverse the PA remodeling through effects on PASMC and inflammatory cells but might simultaneously contribute to reversing RV hypertrophy through primary effects on cardiomyocytes. RV hypertrophy/failure is the most important predictor of morbidity and mortality in PAH (33) . This combination of parallel beneficial effects in both the vascular bed and the heart is highly desirable and might be the first example of a comprehensive, ''transcriptional'' therapy in the diseased RV-pulmonary circulation ''unit'' in PAH.
Kv Channels and PAH. The first description of selective downregulation of Kv channels in PAH, particularly Kv1.5, suggested that these channels are dysfunctional (7), perhaps with a genetic basis. Our work suggests that this is not the case; rather, Kv channel expression is actively suppressed by activated NFAT. Inhibiting NFAT rapidly restores expression of functional Kv channels in PASMC, normalizing Em and [Ca 2ϩ ] i in both human iPAH (Fig. 2 ) and the physiologic ionic remodeling induced by hypoxia (SI Fig. 8 ).
The PASMC depolarization that follows Kv1.5 inhibition leads to two detrimental ionic consequences: influx of Ca 2ϩ [promoting contraction and proliferation (11) ] and accumulation of intracellular K ϩ [which suppresses apoptosis (14)]. Our contention that Kv1.5 is important in PAH is supported by its down-regulation in human and all available models of PAH, including hypoxiainduced, monocrotaline-induced, the fawn-hooded rat, mice overexpressing the serotonin transporter, or transgenic mice with a conditional mutation in BMPR-II (4-6, 8, 9, 34). Moreover, seemingly unrelated experimental therapies that reverse animal PAH in vivo, including the metabolic modulator Dichloroacetate and inhibition of survivin or the serotonin axis, all result in increased PASMC Kv1.5 expression/activity (5, 6, 8) . The regulation of Kv1.5 in all these unrelated models and therapies might have a common denominator, i.e., NFAT. Despite differences in the ''proximal'' part of these mechanisms they might all share a common ''distal'' effector in inducing PAH; this is actually a role that has already been proposed for gene transcription by NFAT, i.e., an integrator and ''choreographer'' of many signaling pathways (19, 24) .
Mitochondria and PAH.
We have suggested that a mitochondrial remodeling might contribute to the apoptosis resistance in PAH and cancer (4) (5) (6) 12) . The role of mitochondria in the pathogenesis of PAH is particularly important because it might help explain why the pathology of PAH is restricted to he pulmonary vessels, sparing the systemic vasculature; given the recently described mitochondrial heterogeneity in the vasculature, where critical differences between PASMC mitochondria and those of systemic arterial smooth muscle cells have been described (35) . The described mitochondrial hyperpolarization in iPAH PASMC is compatible with a resistance to apoptosis state but its etiology remains unknown. NFAT inhibition leads to depolarization of the mitochondria, allowing the efflux of proapoptotic mediators in the cytoplasm. This might be explained by its ability to regulate the expression of bcl-2 ( Fig. 3D and ref. 21) , or several metabolic/mitochondrial enzymes (22, 23) . Conversely, it is possible that NFAT activation is secondary to an earlier and more fundamental mitochondrial abnormality. In fact, the ''retrograde pathway,'' in which NFAT plays an important role, is thought to transmit a ''metabolic'' signal to the nucleus, to coordinate gene transcription with the appropriate metabolic pathways (36). It is not clear whether a primary signal for the pathogenesis of PAH comes from the mitochondria or from NFAT.
Inflammation and PAH. The role of inflammation in vascular remodeling and PAH is incompletely understood. We provide preliminary evidence that NFATc2-activated circulating inflammatory cells are found in the blood and also within the PA wall in PAH patients (Fig. 4) . Several interleukins and TNF-␣ are increased in patients with PAH (26) (27) (28) , and interestingly, many of these cytokines are regulated by NFAT (24) . The NFATc2 levels in scl-PAH patients' blood were the highest among all other groups (Fig. 4B) ; interestingly, scl-PAH has the worst prognosis compared with noninflammatory PAH-associated conditions (3). If our results are confirmed in larger cohorts, then NFAT in the peripheral blood (in the absence of other systemic inflammatory conditions) might be a potential biomarker for PAH.
An NFAT-Based Theory for PAH (Fig. 6) . The NFAT activation likely has a multifactorial etiology in PAH; however, NFAT might be a critical integrator of multiple signaling pathways, and its downstream effects might explain several and important features of PAH (Fig. 6 ). Endothelial dysfunction is one of the earliest abnormalities in PAH, resulting in an imbalance of endothelium-derived vasoactive factors; with increased vasoconstrictors (endothelin, thromboxane, 5-HT; all of which lead to an increase in PASMC [Ca 2ϩ ] i ) and decreased vasodilators (like NO or prostacyclin, which in contrast lead to a decrease in PASMC [Ca 2ϩ ] i ) (2) . The promoted high [Ca 2ϩ ] i -state leads to NFAT activation in PASMC and regulation of multiple genes that might positively reinforce NFAT activation. For example, the down-regulation of Kv1.5 will lead to PASMC depolarization and opening of L-type Ca 2ϩ channels and will sustain the increase in [Ca 2ϩ ] i and thus NFAT activation. The increase in PASMC [Ca 2ϩ ] i might also be promoted by other possibly primary PASMC abnormalities, like the dys-regulated serotonin transporter, up-regulation of TRP channels (37), or decreased SERCA activity (38) . Activation of NFAT will complete a reinforcing positive-feedback loop with the down-regulation of Kv1.5 and may explain why the phenotype is preserved in PASMC in culture, in the absence of endothelium-derived or circulating factors. Multiple NFAT binding elements (i.e., GGAAA) are present in the promoter regions of both the Kv1.5 (20) and bcl-2 (21) genes. Both of these effects will promote a state of proliferation and suppressed mitochondrial-dependent apoptosis. The involvement of NFAT in the inflammatory changes in PAH, and its well known effects in cardiac hypertrophy, suggest that an NFAT inhibition strategy might target PAH with beneficial effects at multiple levels.
The absence of NFAT activation in the PAs (Fig. 1 ) and the peripheral blood of patients with secondary pulmonary hypertension (Fig. 4) is intriguing and supports that our findings are not secondary to the vascular remodeling and the increased pressures per se; however, the limited examples of this condition in our study do not allow for generalization of this finding.
NFAT Activation in Both PAH and Cancer. Intriguing similarities in the apoptosis resistance in PAH and in cancer have started being recognized (28) . The oncoprotein survivin is expressed in the PAH PA media and a cancer-based strategy to inhibit endogenous survivin leads to reversal of PAH (5). Monocrotaline-PAH has been shown to be reversed by the anticancer drug Gleevec (39) . We recently reported that a similar to PAH Kv1.5 and mitochondrial remodeling (down-regulated Kv1.5 and hyperpolarized mitochondria) is present in several cancer cell lines (12) . Cancer growth in vitro and in vivo was inhibited by the mitochondria-targeting drug Dichloroacetate, which reversed both the ionic and mitochondrial remodeling in cancer in a manner identical to that in PAH (6) . Intriguingly, it appears that this ionic-mitochondrial remodeling in cancer is also mediated by NFATc2 activation (12) . Direct inhibition of NFATc2 in cancer cells by VIVIT reversed the downregulation of Kv1.5, decreasing proliferation and inducing apoptosis. The current and recent findings suggest that the NFAT-Kv channel-mitochondria axis regulates ionic and metabolic remodeling and apoptosis in diverse conditions ranging from vascular disease and myocardial hypertrophy to cancer.
Methods
Confocal Microscopy. Imaging was performed in frozen or paraffinembedded tissues or cultured cells, using a Zeiss (Thornwood, NY) LSM 510 model as described in refs. 5 and 12. For details, sources, and strengths for antibodies, see SI Text. PASMC in Culture. PASMC cell lines were established from resistance PAs both from iPAH (patient 7) and patients with normal pulmonary circulation (patients 1, 2) as described in ref. 5 . After enzymatic isolation, PASMC were kept at 37°C in DMEM supplemented with 10% FBS and 1% PSF (PO 2 Ϸ120 mm Hg/PCO 2 Ϸ40 mm Hg, pHϷ7.2). For hypoxic experiments, healthy PASMC were kept for 96 h in a hypoxic incubator (4% O 2 /PO 2 45 Ϯ 5 mm Hg) and pH (Ϸ7.3 Ϯ 0.1) as described in ref. 4 . PASMC were treated with the cell-permeable NFAT inhibitor 11R-VIVIT (EMD Biosciences, Mississaga, ON, Canada) for 48 h (4 M) (29) or antennapedia, (EMD Biosciences) (48 h, 4 M) (30) or Cyclosporine A (EMD Biosciences) (0.03 mg⅐ml Ϫ1 , 48 h). All drugs were dissolved in PBS, and pH was normalized.
Ca 2ϩ measurements, K ϩ measurements, and electrophysiology were performed as described in refs. 5, 6, and 12. See also SI Text.
Immunoblotting. PASMC or PAs were collected, and immunoblotting was performed on pooled samples from four T-25 dishes or four rats (25 g of protein in pooled samples per lane) and normalized to smooth muscle actin, as described in refs. 5, 6, and 12.
Quantitative RT-PCR. qRT-PCR was performed in an ABI PRISM 7700 Sequence Detector (Applied Biosystems) and commercially available primers (5, 6, and 12).
In Vivo Rat Studies. Male Sprague-Dawley rats were injected with monocrotaline as described in refs. 5 and 6. Mean PA pressure, cardiac output, total pulmonary resistance, percentage of medial thickness of small-medium PAs (100-400 m), and right ventricular hypertrophy were measured as described in refs. 5 and 6. Rats with established monocrotaline-PAH were randomized to receive cyclosporine (1 mg/kg per os ϫ 2 weeks), or vehicle (water).
Statistics. Values are expressed as the mean Ϯ SEM. Intergroup differences were assessed by Kruskal-Wallis or one-way ANOVA, with post hoc analysis, using Fisher's exact test ( * , P Ͻ 0.05).
